Stanford MEDICINE
School of Medicine

Weight gain during Menopause: Solutions in the Era of GLP1- agonists

Sharon W. Hung MD
Assistant Clinical Professor
Director of Women's Health
Primary Care and Population Health

Disclosures

I have no disclosures

Roadmap

Obesity definitions

Effects of menopause vs. aging

Weight loss medications

Addressing barriers to GLP1a use

Counseling on diet & exercise

Obesity definition: WHO

Classification	BMI (kg/m^2)	
	Caucasian	South Asian* and Chinese
Healthy or 'normal' weight	18.5–24.9	18.5–23
Overweight or preobesity	25–29.9	23–27.5
Obesity I	30–34.9	≥27.5
Obesity II	35–39.9	
Obesity III	≥40	

*South Asian = Bangladesh, Bhutan, India, Indian-Caribbean (immigrants of South Asian family origin), Maldives, Nepal, Pakistan and Sri Lanka
BMI, body mass index.

We no longer using the term "morbid obesity".

Lower threshold by 2 kg/m2 for South Asian, Southeast Asian, and East Asian genetic heredity, as health risks associated with overweight and obesity typically are observed at lower BMIs in these populations

Obesity Medicine Association definition:

Obesity is a chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences

Patient preferred terms:



Volger S, Vetter ML, Dougherty M, Panigrahi E, Egner R, Webb V, Thomas JG, Sarwer DB, Wadden TA. Patients' preferred terms for describing their excess weight: discussing obesity in clinical practice. Obesity (Silver Spring). 2012 Jan;20(1):147-50. doi: 10.1038/oby.2011.217. Epub 2011 Jul 14. PMID: 21760637; PMCID: PMC3310899.

Rising rates of obesity

In the United States:[1,2]

31% have overweight (BMI ≥25 kg/m²)

42% have obesity (BMI ≥30 kg/m²)

Obesity is associated with an increased risk of CVD and CVD-associated mortality[4]





https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html



https://whfoods.com/blog/obesity-statistics/

Weight gain: menopause or aging??

Menopause (estrogen deficiency)
Impaired muscle maintenance/repair
Increased visceral and subcutaneous fat
- Increased risk of CVD

Aging effects:
Average weight gain: 1-2 pounds/year
Studies show weight gain independent of menopausal status
Muscle mass loss
- Decreased BMR and RMR



Risks associated with menopausal weight gain



Weight gain

Visceral Obesity

↑Cardiometabolic disease risk
- Type 2 diabetes
- Dyslipidemia
- Hypertension
- Non-alcoholic fatty liver disease
- Metabolic syndrome

↑Cancer risk
- Breast cancer
- Endometrial cancer
- Ovarian cancer

↑Mechanical complications
- Osteoarthritis
- Obstructive sleep apnea
- Gastroesophageal reflux disease

↑Mental health disorders

↑Menopause symptoms

Hurtado MD, Saadedine M, Kapoor E, Shufelt CL, Faubion SS. Weight Gain in Midlife Women. Curr Obes Rep. 2024 Jun;13(2):352-363. doi: 10.1007/s13679-024-00555-2. Epub 2024 Feb 28. PMID: PMCID: PMC11150086.

So can menopausal hormone therapy help with midlife weight gain…. ?

- MHT has been associated with
  - Decreased visceral adiposity, total adiposity
  - Decreased muscle mass loss
  - Improved metabolic parameters- ie insulin resistance
  - *Effect size is small*

- **MHT should not be prescribed for concern of body composition and weight gain alone**

- **MHT is considered weight neutral**

Stanford MEDICINE | School of Medicine



Weight loss pharmacotherapy

Consider when:

BMI ≥ 30 kg/m2 OR

BMI ≥ 27 kg/m2 with 1+ weight-related comorbidities

Start with:

Comprehensive lifestyle intervention:

a combination of diet, exercise, and behavioral modification

Review barriers to healthy eating and regular exercise.

Review current medication list!

Stanford MEDICINE | School of Medicine

Review current medication list first!

Class	Drugs that may promote weight gain	Consider alternatives
Diabetes	Insulin, sulfonylureas, TZDs	GLP1 agonists, SGLT2i, metformin - weight loss DPP4i, alpha glucosidase inhibitor - weight neutral
HTN	Atenolol, Metoprolol, Propranolol	ACEI/ARB preferred. CCB weight neutral Carvedilol, nebivolol if indication for BB
Anti-depressants	**Paroxetine, Amitriptyline**, Nortriptyline, **Mirtazapine,** Venlafaxine, Duloxetine **Lithium**	**Buproprion** - weight loss Fluoxetine, Sertraline, Vortioxetine – weight loss/neutral Citalopram, Escitalopram - weight neutral
Anti-psychotics	Olanzapine, Clozapine, Risperidone, Quetiapine	Ziprasidone, Aripiprazole, Haloperidol
Anti-epileptics	Gabapentin, Pregabalin, Valproic acid, Carbamazepine	Topiramate, Zonisamide - weight loss Lamotrigine, Levetiracetam, Phenytoin - weight neutral

Caroline M. Apovian, Louis J. Aronne, et al Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, *The Journal of Clinical Endocrinology & Metabolism*, Volume 100, Issue 2, 1 February 2015, Pages 342–362,

GLP-1 agonists approved for weight loss

Semaglutide 2.4 mg weekly (2021) and Liraglutide 3.0 mg daily (2014)

- Slows gastric emptying
- Alters brain's reward pathways related to food
- Improves glycemic control

STEP 1 trial: -14.9 % body weight change on Semaglutide 2.4mg
(12.4% change for treatment difference from placebo)



Tirzepatide: Dual GLP-1 & GIP



SURMONT-1 study

In overweight/obese patients without DM2, mean weight loss on 15mg dose: -20.9%

** approved 2023 for weight loss (Zepbound)

Stanford MEDICINE | School of Medicine

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216.

GLP1 receptor agonists: Weight loss & MACE reduction

Weight loss *(mean % change in body weight)*
Data from people with obesity/overweight without T2D

MACE *(% of patients with primary composite outcome of time to first occurrence of MACE)*
Data from people with T2D

Liraglutide (s.c. 3 mg)[68] – (s.c. 0.5 and 1.0 mg)[53]	Semaglutide (s.c. 2.4 mg)[71] – (s.c. 0.5 and 1.0 mg)[54]	Tirzepatide (s.c. 5, 10 and 15 mg)[78]	Dulaglutide (s.c. 1.5 mg)[59]
–8.0% / –2.6%	–14.9% / –2.4%	–15.0% –19.5% / –3.1% –20.9%	-- / --
13.0% / 14.9%	6.6% / 8.9%	-- / --	12.0% / 13.4%
LEADER (2016)	Sustain 6 (2016)	SURPASS CVOT (ongoing)	REWIND (2011)

Stanford MEDICINE | School of Medicine

GLP1a FDA-approved for weight loss

Name/Dose	Percentage body weight loss	Contraindications	Side effects	Considerations
Tirzepatide (Zepbound 15mg) Titrate monthly: 2.5, 5, 7.5,10,12.5,15mg Weekly injection	**20.9%** at 72 weeks	Medullary thyroid cancer, MEN2, Pancreatitis Pregnancy Gastroparesis/SBO	Nausea/vomiting, abdominal pain, diarrhea/constipation, ha, fatigue	**DM2** **OSA** (SURMOUNT-OSA) MASH (SYNERGY-NASH)
Semaglutide (Wegovy 2.4 mg) Titrate monthly: 0.25, 0.5, 1, 1.7. 2.4 mg Weekly injection	**14.9%** mean at 68 weeks	Same	Same	**DM2** HFpEF (STEP HFpEF) **CV risk** (SUSTAIN 6) OA (STEP 9) **CKD** (FLOW) MASH (ESSENCE) *Alzheimer's? (EVOKE)*
Liraglutide (Saxenda 3mg) Titrate weekly: 0.6, 1.2, 1.8, 2.4, 3mg Daily injection	**5-10%** at 56 weeks **6.1%** at 3 years	Same	Same	**DM2** CKD (LEADER) MASH (LEAN) **CV risk** (LEADER) OSA (ROMANCE)

Numerous other agents in the pipeline





Melson, E., Ashraf, U., Papamargaritis, D. *et al.* What is the pipeline for future medications for obesity?. *Int J Obes* (2024). https://doi.org/10.1038/s41366-024-01473-y

Retatrutide: Triple Agonist for Weight Loss

GLP1 + GIP + glucagon agonist

Phase 2 trial results shown (currently in phase 3)

338 adults with BMI >30 mg/kg^2 or BMI >27 + comorbidity

Retratrutide vs placebo weekly x 48 weeks

Mean percentage change of **-24.2 %** for patients on maximum dose of 12mg, compared with 2.1% in placebo.



Retatrutide Phase 2 Obesity Trial Investigators. N Engl J Med 2023;389:514-526

Addressing barriers to GLP-1 agonist use

Insurance coverage
Cost

Shortages

Patient hesitation,
Side effects

Insurance coverage: Tips

Private insurance coverage varies significantly.

Medicare does not currently cover for weight loss. Medicaid in CA does (1 of 16 states)

- Ensure order is for GLP1a that is FDA approved for weight loss: Zepbound, Wegovy, Saxenda
- Include **ICD-10 codes** with GLP1a orders ie with ”Stage 1 Obesity” or “BMI 31-31.9"

<u>Careful documentation:</u>

- **BMI:** highest BMI, starting BMI, weight progress on medications (BMI may need to be measured in office)
- Evidence of engaging in **“weight loss program”:** working with nutritionist, took nutrition or weight loss class, current exercise/diet regimen, used program like Noom or Weight Watchers etc, weight loss medications that have been tried and failed

Advise patients to request refills and dose increases at least 1 week before

for update on weight and tolerance to ensure there is sufficient time in case of shortage or coverage issue

If no insurance coverage for weight loss medications:

- Liraglutide is now generic
  - Good Rx: $524 for six 18 mg pens (~1 month supply of the 3mg dose)

- Cost savings cards
  - Cost around $650 per month instead of $1100-1300/month
  - CANNOT be in any government funded health program, ie Medicare and Medicaid



- Zepbound vials

Zepbound vials - cash pay

Zepbound 2.5 mg vials is **$349 per month** , Zepbound 5, 10 and 15mg are **$499 per month**.

- No insurance coverage, but patients can use their FSA/HSA
- Include an ICD-10 code on order
- Must send to **LillyDirect® Cash Pay Pharmacy Solutions**
- Patient will receive email/text to pay and complete the order

.

1

The Zepbound vial will be listed in one of two ways depending on the EHR system used in your organization.

To prescribe, select:

- Zepbound Subcutaneous Solution 2.5 MG/0.5 ML | Zepbound Subcutaneous Solution 5 MG/0.5 ML **OR**
- ZEPBOUND 2.5 MG/0.5 ML VIAL | ZEPBOUND 5.0 MG/0.5 ML VIAL

You can also search for the Zepbound Vial by NDC:

- Zepbound Vial 2.5 mg NDC: 0002-0152-04
- Zepbound Vial 5 mg NDC: 0002-0243-04

If you cannot identify the vial presentation in your drug listing, you can also indicate that you are prescribing vials in the Notes/Sig sections.

2

To select the **pharmacy** in the EHR system, select **LillyDirect® Cash Pay for Zepbound Vial**

- When searching for LillyDirect in EHR, two options will appear. Be sure to select **LillyDirect Cash Pay for Zepbound Vial**
- You may also navigate to the LillyDirect Cash Pay for Zepbound Vial by searching NPI: 1689411712 or NCPDP: 3692539
- No prior authorization is needed or accepted, and Zepbound vials are limited to patients with an on-label ICD-10 code. Typically, there is a diagnosis code field within the electronic prescription. If that is not an option, you can document the ICD-10 code(s) in the Notes or Sig section

FDA cautions AGAINST compounded semaglutide

Stanford MEDICINE | School of Medicine

Solutions to: Shortages

*If 1-2 doses are missed, can generally restart at the same dose.

TABLE 4 GLP-1 Receptor Agonist Drug Shortages and Suggested Comparative Doses for Treating Type 2 Diabetes

Agent	Dosing Route and Interval	Comparative Doses								
Exenatide	SC twice daily	5 μg*	10 μg							
Lixisenatide	SC once daily	10 μg*	20 μg							
Liraglutide	SC once daily	0.6 mg*	1.2 mg	1.8 mg						
Exenatide XR	SC once weekly			2 mg						
Dulaglutide	SC once weekly		0.75 mg[a]*	1.5 mg[a]	3 mg[b]†	4.5 mg[b]†				
Semaglutide	SC once weekly		0.25 mg[b]*	0.5 mg[b]		1 mg[a]	2 mg[a]‡			
Semaglutide	PO once daily	3 mg*	7 mg	14 mg						
Tirzepatide	SC once weekly			2.5 mg[a]*			5 mg[a]‡	7.5 mg[a]	10 mg[a]	12.5 mg[a]	15 mg[a]

Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clin Diabetes. 2023 Summer;41(3):467-473. doi: 10.2337/cd23-0023. Epub 2023 Apr 7. Erratum in: Clin Diabetes. 2024 Aug 13;42(4):583.

Stanford MEDICINE | School of Medicine

Cost: Consider alternative weight loss medications

Medication	Percentage body weight loss	Cost : 1 month supply GoodRx	Contraindications	Side effects	Indications to consider
Tirzepatide	20.9% at 72 weeks	$1090 $ 630 with Zepbound savings card	Medullary thyroid cancer, MEN2, Pancreatitis	Nausea/vomiting, abdominal pain, diarrhea/constipation, ha, fatigue	DM2, OSA MASH
Semaglutide	14.9% mean at 68 weeks	$1300 $650 with Wegovy savings card	Same for GLP1a	Same for GLP1a	DM2, HFpEF CV risk, OA, CKD
Phenteramine/ Topiramate	9-14% at 1 year 10% at 2 years	$150 combo OR $12 + 4 separately	Uncontrolled HTN, CVD, Hyperthyroidism, glaucoma, nephrolithiasis, MAOI in last 14 days	Constipation, dizziness, depression, insomnia, parasthesias Monitor HR, BMP	Migraines Seizure d/o
Liraglutide	5-10% at 56 weeks 6.1% at 3 years	$520 on GoodRx	Same for GLP1a	Same for GLP1	DM2, CKD, OSA MASH, CV risk
Naltrexone/Buproprion	5-8% at 56 weeks 3-5% at 2 years	$560 combo OR $35 + 6 separately	Uncontrolled HTN, seizure d/o, restrictive eating disorder, withdrawal of substances	Nausea/vomiting, diarrhea/constipation, insomnia, HA, dizziness Monitor for SI	Depression Etoh use d/o Smokers
Orlistat	3% at 1 year	$207	Chronic malabsorption, cholestasis	Steatorrhea, diarrhea, abdominal pain	

Patient Education:GLP1ra

Who should take a GLP-1ra?

- ❑ **Heart and Blood Vessel Disease (ASCVD)**
  or
- ❑ **High risk for ASCVD**

Taking a GLP-1ra may improve your heart health even if your A1c is in goal

How do GLP-1ra work?

- Make body more sensitive to insulin
- Lower blood sugar levels after meals
- Slow stomach emptying
- Decrease appetite and cravings

*Tirzepatide can reduce effectiveness of oral COC

Not to be used during pregnancy. Liraglutide/Semaglutide might be compatible with breastfeeding, but weight loss reduces supply

Why take a GLP-1ra?

- Lower the risks of heart attack, stroke, and dying from heart disease
- Decrease blood sugar (A1c) with minimal risk of low blood sugar

As well as...

- Weight loss
- Modest decrease in blood pressure

What to expect when taking a GLP-1ra:

Benefits shown in studies:

- A1c decrease of about 0.4% to 1.4%

Common SE:

- Nausea

Less common SE:

- Diarrhea
- Abdominal pain

How to prevent or manage side effects

	What to watch for:	How to avoid:
Nausea	Feeling overly full Queasiness Urge to vomit Stomach discomfort	Reduce meal size by 50% Begin meal with protein Avoid meals larger than fist size Stop eating when full, even if meal is not finished
Constipation	Less frequent bowel movements Stools are hard to pass or painful Stools are dry and hard	Increase fiber in diet and stay well-hydrated Avoid drinks with alcohol or caffeine Consider use of stool softener if needed
Low blood sugar	Shakiness Sweatiness Dizziness Fatigue Irritability	Avoid skipping meals Time medications based on meals Monitor blood sugar more often If needed, discuss changes to other diabetes medication with your doctor

How to decrease risk of diabetes complications

PCNA
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION

Weight regain after discontinuation of GLP1a



STEP 1 treatment phase included semaglutide 2.4 PLUS
- Dietary counseling every month
- 500kcal daily deficit
- 150 minute minutes of exercise weekly

STEP 1 extension:

1 year after withdrawal of weekly sq semaglutide 2.4 mg
(Lifestyle intervention counseling did not continue)

- participants regained 2/3rd of weight loss
  - regained a mean of 11.6% of body weight loss
    - (net body weight loss of only 5.6%)

Similar changes in cardiometabolic profiles (A1c, lipids, CRP)

Blood pressure reverted back to baseline despite overall weight loss

**** highlights chronicity of obesity, and a *need for maintenance therapy*.**

Exercise prescription



Impact on weight

Meeting minimum physical activity does NOT lead to weight loss WITHOUT caloric restriction

Exercise is critical for:

- cardiometabolic health
- weight maintenance
- reduces visceral adiposity
- reduces lean muscle mass loss

GLP1a usage associated with significant lean & muscle mass loss



João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H. Naylor, P. Gerry Fegan, Bu B. Yeap, Daniel J. Green; Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. *Diabetes Care* 20 September 2024; 47 (10): 1718–1730

Emphasize resistance training



- For patients on a weight loss program**, resistance training alone** results in less lean muscle mass loss than endurance training alone, or in combination.
- **Liraglutide + cardio + strength exercise** → greatest weight loss, increase muscle mass, and increased cognitive restraint
- Hypothesized that there would be **less weight regain** on discontinuation of therapy if strength training is done due to increased muscle mass
- Advise strength training ideally **3 times a week** working all major muscle groups.

“Which diet should I choose?”

Dietary adherence is the primary predictor of weight loss, regardless of the type of diet chosen

Caloric deficit of >500 kcal for weight loss
Ie ~ 1200-1500 kcal intake daily for most women

Consider diets that reduce cardiovascular risk:
i.e. Mediterranean, DASH diet, plant-based diet

Intermittent fasting data on weight loss is mixed, likely only helpful the patients where this helps with caloric restriction

Protein intake!

Protein intake of **>30% of total intake** or **1.2 g/kg of body weight** has demonstrated favorable effects on body composition during weight loss intervention in middle- aged women

** continue protein of 0.8g/kg for non-HD CKD 3-5



Obesity treatment pyramid developed by Angela Fitch, MD

Tucker, Shanna & Bramante, Carolyn & Conroy, Molly & Fitch, Angela & Gilden, Adam & Wittleder, Sandra & Jay, Melanie. (2021). The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings. Current Obesity Reports. 10. 10.1007/s13679-021-00444-y.

Bariatric surgery with 62% reduction in mortality compared to GLP-1RAs



Dicker D, Sagy YW, Ramot N, Battat E, Greenland P, Arbel R, Lavie G, Reges O. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality. JAMA Netw Open. 2024 Jun 3;7(6):e2415392. doi: 10.1001/jamanetworkopen.2024.15392. PMID: 38848064; PMCID: PMC11161844.

Factors affecting weight set point

- Genetics
- Weight promoting medications
- Sleep deprivation, insomnia
- Disrupted circadian rhythm
- Untreated sleep apnea
- Chronic stress
- Dietary habits
- Food insecurities/access issues
- Family/cultural traditions
- Physical inactivity
- Endocrine: ie thyroid or cortisol
- Mental health disorders
- Substance abuse
- Access to mental health care

Summary

- Aging causes weight gain and muscle mass loss, but menopause contributes to increased visceral adiposity

- Caloric restriction is essential for weight loss
- Advise patients to work alongside nutritionist for maximal benefit

- Critical to counsel patients on resistance exercise 2-3 x/week and increasing protein intake to 1.2 g/kg to avoid lean muscle mass loss associated with both aging and weight loss in addition to regular cardio

- GLP1a reduce risk of MACE, and also have benefits in HFpEF, CKD, OSA, MASLD, and OA. Tirzepatide is the most effective drug at this time, but there are many on the pipeline
- If patient's insurance does not cover GLP1a for weight loss, can use generic liraglutide, cost savings card or vials, however cost is still substantial at $500-600/month
- Consider off-label combinations of individual medications for maximal cost savings
- Prepare patients that maintenance dose will likely be needed to maintain weight that is lost
- Remember that bariatric surgery is still the most effective, with significant mortality benefit in diabetics.

- For long term success, assess for other factors that can affect weight set point: ie medication side effects, mental health disorders, lack of sleep, OSA, chronic stress, access to food and healthcare, etc

Thank you !

swhung@Stanford.edu